Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study
Identifieur interne : 001E65 ( Main/Corpus ); précédent : 001E64; suivant : 001E66Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study
Auteurs : Yasuo Toyokura ; Yoshikuni Mizuno ; Masao Kase ; Itsuro Sobue ; Yoshigoro Kuroiwa ; Hirotaro Narabayashi ; Masanori Uono ; Takao Nakanishi ; Masakuni Kameyama ; Hitoshi Ito ; Yasuo Shimada ; Makoto IwataSource :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1985-08.
English descriptors
Abstract
ABSTRACT – The effects of bromocriptine in patients with Parkinson's disease manifesting various problems in levodopa therapy were tested in a double‐blind manner with the collaboration of 59 institutions. The slow and low principle was in part adopted. Either bromocriptine or placebo was added to levodopa. Twenty‐nine % of the bromocriptine‐treated patients (n = 108), in contrast to 14.8% of the placebo‐treated (n = 108), showed either marked or moderate improvement (P < 0.05). Twenty to 37% improvement was noted in most of the symptoms studied in those treated with bromocriptine. The significant superiority of bromocriptine was also noted in the effects on wearing‐off phenomena and frozen gait. No irreversible side effects were noted. It is concluded that bromocriptine is useful in patients who are manifesting various difficulties in levodopa therapy. Our results are comparable to those using higher maintenance doses. Dopamine antagonistic actions were not observed. This is unlike the case with experimental animals.
Url:
DOI: 10.1111/j.1600-0404.1985.tb00858.x
Links to Exploration step
ISTEX:D9CCAF44E90C2E5D3BE1C482AC1684214A0F950FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study</title><author><name sortKey="Toyokura, Yasuo" sort="Toyokura, Yasuo" uniqKey="Toyokura Y" first="Yasuo" last="Toyokura">Yasuo Toyokura</name><affiliation><mods:affiliation>Department of Neurology, University of Tokyo</mods:affiliation></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><mods:affiliation>Department of Neurology, Jichi Medical School</mods:affiliation></affiliation></author><author><name sortKey="Kase, Masao" sort="Kase, Masao" uniqKey="Kase M" first="Masao" last="Kase">Masao Kase</name><affiliation><mods:affiliation>Segawa Neurology Clinic of Children</mods:affiliation></affiliation></author><author><name sortKey="Sobue, Itsuro" sort="Sobue, Itsuro" uniqKey="Sobue I" first="Itsuro" last="Sobue">Itsuro Sobue</name><affiliation><mods:affiliation>First Department of Medicine, University of Nagoya</mods:affiliation></affiliation></author><author><name sortKey="Kuroiwa, Yoshigoro" sort="Kuroiwa, Yoshigoro" uniqKey="Kuroiwa Y" first="Yoshigoro" last="Kuroiwa">Yoshigoro Kuroiwa</name><affiliation><mods:affiliation>Department of Neurology, Kyushu University</mods:affiliation></affiliation></author><author><name sortKey="Narabayashi, Hirotaro" sort="Narabayashi, Hirotaro" uniqKey="Narabayashi H" first="Hirotaro" last="Narabayashi">Hirotaro Narabayashi</name><affiliation><mods:affiliation>Department of Neurology, Juntendo University</mods:affiliation></affiliation></author><author><name sortKey="Uono, Masanori" sort="Uono, Masanori" uniqKey="Uono M" first="Masanori" last="Uono">Masanori Uono</name><affiliation><mods:affiliation>National Shizuoka Hospital</mods:affiliation></affiliation></author><author><name sortKey="Nakanishi, Takao" sort="Nakanishi, Takao" uniqKey="Nakanishi T" first="Takao" last="Nakanishi">Takao Nakanishi</name><affiliation><mods:affiliation>Department of Neurology, University of Tsukuba</mods:affiliation></affiliation></author><author><name sortKey="Kameyama, Masakuni" sort="Kameyama, Masakuni" uniqKey="Kameyama M" first="Masakuni" last="Kameyama">Masakuni Kameyama</name><affiliation><mods:affiliation>Department of Neurology, University of Kyoto</mods:affiliation></affiliation></author><author><name sortKey="Ito, Hitoshi" sort="Ito, Hitoshi" uniqKey="Ito H" first="Hitoshi" last="Ito">Hitoshi Ito</name><affiliation><mods:affiliation>Department of Psychiatry, Keio University</mods:affiliation></affiliation></author><author><name sortKey="Shimada, Yasuo" sort="Shimada, Yasuo" uniqKey="Shimada Y" first="Yasuo" last="Shimada">Yasuo Shimada</name><affiliation><mods:affiliation>Shimada Hospital</mods:affiliation></affiliation></author><author><name sortKey="Iwata, Makoto" sort="Iwata, Makoto" uniqKey="Iwata M" first="Makoto" last="Iwata">Makoto Iwata</name><affiliation><mods:affiliation>Department of Neurology, University of Tokyo</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F</idno><date when="1985" year="1985">1985</date><idno type="doi">10.1111/j.1600-0404.1985.tb00858.x</idno><idno type="url">https://api.istex.fr/document/D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001E65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study</title><author><name sortKey="Toyokura, Yasuo" sort="Toyokura, Yasuo" uniqKey="Toyokura Y" first="Yasuo" last="Toyokura">Yasuo Toyokura</name><affiliation><mods:affiliation>Department of Neurology, University of Tokyo</mods:affiliation></affiliation></author><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation><mods:affiliation>Department of Neurology, Jichi Medical School</mods:affiliation></affiliation></author><author><name sortKey="Kase, Masao" sort="Kase, Masao" uniqKey="Kase M" first="Masao" last="Kase">Masao Kase</name><affiliation><mods:affiliation>Segawa Neurology Clinic of Children</mods:affiliation></affiliation></author><author><name sortKey="Sobue, Itsuro" sort="Sobue, Itsuro" uniqKey="Sobue I" first="Itsuro" last="Sobue">Itsuro Sobue</name><affiliation><mods:affiliation>First Department of Medicine, University of Nagoya</mods:affiliation></affiliation></author><author><name sortKey="Kuroiwa, Yoshigoro" sort="Kuroiwa, Yoshigoro" uniqKey="Kuroiwa Y" first="Yoshigoro" last="Kuroiwa">Yoshigoro Kuroiwa</name><affiliation><mods:affiliation>Department of Neurology, Kyushu University</mods:affiliation></affiliation></author><author><name sortKey="Narabayashi, Hirotaro" sort="Narabayashi, Hirotaro" uniqKey="Narabayashi H" first="Hirotaro" last="Narabayashi">Hirotaro Narabayashi</name><affiliation><mods:affiliation>Department of Neurology, Juntendo University</mods:affiliation></affiliation></author><author><name sortKey="Uono, Masanori" sort="Uono, Masanori" uniqKey="Uono M" first="Masanori" last="Uono">Masanori Uono</name><affiliation><mods:affiliation>National Shizuoka Hospital</mods:affiliation></affiliation></author><author><name sortKey="Nakanishi, Takao" sort="Nakanishi, Takao" uniqKey="Nakanishi T" first="Takao" last="Nakanishi">Takao Nakanishi</name><affiliation><mods:affiliation>Department of Neurology, University of Tsukuba</mods:affiliation></affiliation></author><author><name sortKey="Kameyama, Masakuni" sort="Kameyama, Masakuni" uniqKey="Kameyama M" first="Masakuni" last="Kameyama">Masakuni Kameyama</name><affiliation><mods:affiliation>Department of Neurology, University of Kyoto</mods:affiliation></affiliation></author><author><name sortKey="Ito, Hitoshi" sort="Ito, Hitoshi" uniqKey="Ito H" first="Hitoshi" last="Ito">Hitoshi Ito</name><affiliation><mods:affiliation>Department of Psychiatry, Keio University</mods:affiliation></affiliation></author><author><name sortKey="Shimada, Yasuo" sort="Shimada, Yasuo" uniqKey="Shimada Y" first="Yasuo" last="Shimada">Yasuo Shimada</name><affiliation><mods:affiliation>Shimada Hospital</mods:affiliation></affiliation></author><author><name sortKey="Iwata, Makoto" sort="Iwata, Makoto" uniqKey="Iwata M" first="Makoto" last="Iwata">Makoto Iwata</name><affiliation><mods:affiliation>Department of Neurology, University of Tokyo</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1985-08">1985-08</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="170">170</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F</idno><idno type="DOI">10.1111/j.1600-0404.1985.tb00858.x</idno><idno type="ArticleID">ANE157</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bromocriptine</term><term>Japan</term><term>Parkinson's disease</term><term>Parkinsonism</term><term>double‐blind study</term><term>levodopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ABSTRACT – The effects of bromocriptine in patients with Parkinson's disease manifesting various problems in levodopa therapy were tested in a double‐blind manner with the collaboration of 59 institutions. The slow and low principle was in part adopted. Either bromocriptine or placebo was added to levodopa. Twenty‐nine % of the bromocriptine‐treated patients (n = 108), in contrast to 14.8% of the placebo‐treated (n = 108), showed either marked or moderate improvement (P < 0.05). Twenty to 37% improvement was noted in most of the symptoms studied in those treated with bromocriptine. The significant superiority of bromocriptine was also noted in the effects on wearing‐off phenomena and frozen gait. No irreversible side effects were noted. It is concluded that bromocriptine is useful in patients who are manifesting various difficulties in levodopa therapy. Our results are comparable to those using higher maintenance doses. Dopamine antagonistic actions were not observed. This is unlike the case with experimental animals.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Yasuo Toyokura</name><affiliations><json:string>Department of Neurology, University of Tokyo</json:string></affiliations></json:item><json:item><name>Yoshikuni Mizuno</name><affiliations><json:string>Department of Neurology, Jichi Medical School</json:string></affiliations></json:item><json:item><name>Masao Kase</name><affiliations><json:string>Segawa Neurology Clinic of Children</json:string></affiliations></json:item><json:item><name>Itsuro Sobue</name><affiliations><json:string>First Department of Medicine, University of Nagoya</json:string></affiliations></json:item><json:item><name>Yoshigoro Kuroiwa</name><affiliations><json:string>Department of Neurology, Kyushu University</json:string></affiliations></json:item><json:item><name>Hirotaro Narabayashi</name><affiliations><json:string>Department of Neurology, Juntendo University</json:string></affiliations></json:item><json:item><name>Masanori Uono</name><affiliations><json:string>National Shizuoka Hospital</json:string></affiliations></json:item><json:item><name>Takao Nakanishi</name><affiliations><json:string>Department of Neurology, University of Tsukuba</json:string></affiliations></json:item><json:item><name>Masakuni Kameyama</name><affiliations><json:string>Department of Neurology, University of Kyoto</json:string></affiliations></json:item><json:item><name>Hitoshi Ito</name><affiliations><json:string>Department of Psychiatry, Keio University</json:string></affiliations></json:item><json:item><name>Yasuo Shimada</name><affiliations><json:string>Shimada Hospital</json:string></affiliations></json:item><json:item><name>Makoto Iwata</name><affiliations><json:string>Department of Neurology, University of Tokyo</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Bromocriptine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>double‐blind study</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Japan</value></json:item></subject><articleId><json:string>ANE157</json:string></articleId><language><json:string>eng</json:string></language><abstract>ABSTRACT – The effects of bromocriptine in patients with Parkinson's disease manifesting various problems in levodopa therapy were tested in a double‐blind manner with the collaboration of 59 institutions. The slow and low principle was in part adopted. Either bromocriptine or placebo was added to levodopa. Twenty‐nine % of the bromocriptine‐treated patients (n = 108), in contrast to 14.8% of the placebo‐treated (n = 108), showed either marked or moderate improvement (P > 0.05). Twenty to 37% improvement was noted in most of the symptoms studied in those treated with bromocriptine. The significant superiority of bromocriptine was also noted in the effects on wearing‐off phenomena and frozen gait. No irreversible side effects were noted. It is concluded that bromocriptine is useful in patients who are manifesting various difficulties in levodopa therapy. Our results are comparable to those using higher maintenance doses. Dopamine antagonistic actions were not observed. This is unlike the case with experimental animals.</abstract><qualityIndicators><score>7.36</score><pdfVersion>1.4</pdfVersion><pdfPageSize>504 x 720 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1033</abstractCharCount><pdfWordCount>6668</pdfWordCount><pdfCharCount>43472</pdfCharCount><pdfPageCount>14</pdfPageCount><abstractWordCount>155</abstractWordCount></qualityIndicators><title>Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study</title><genre><json:string>article</json:string></genre><host><volume>72</volume><publisherId><json:string>ANE</json:string></publisherId><pages><total>14</total><last>170</last><first>157</first></pages><issn><json:string>0001-6314</json:string></issn><issue>2</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0404</json:string></eissn><title>Acta Neurologica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0404</json:string></doi></host><publicationDate>1985</publicationDate><copyrightDate>1985</copyrightDate><doi><json:string>10.1111/j.1600-0404.1985.tb00858.x</json:string></doi><id>D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1985</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study</title><author><persName><forename type="first">Yasuo</forename><surname>Toyokura</surname></persName><affiliation>Department of Neurology, University of Tokyo</affiliation></author><author><persName><forename type="first">Yoshikuni</forename><surname>Mizuno</surname></persName><note type="correspondence"><p>Correspondence: , M.D. Department of Neurology Jichi Medical School 3311 Yakushiji, Minamikawachi Tochigi Japan</p></note><affiliation>Department of Neurology, Jichi Medical School</affiliation></author><author><persName><forename type="first">Masao</forename><surname>Kase</surname></persName><affiliation>Segawa Neurology Clinic of Children</affiliation></author><author><persName><forename type="first">Itsuro</forename><surname>Sobue</surname></persName><affiliation>First Department of Medicine, University of Nagoya</affiliation></author><author><persName><forename type="first">Yoshigoro</forename><surname>Kuroiwa</surname></persName><affiliation>Department of Neurology, Kyushu University</affiliation></author><author><persName><forename type="first">Hirotaro</forename><surname>Narabayashi</surname></persName><affiliation>Department of Neurology, Juntendo University</affiliation></author><author><persName><forename type="first">Masanori</forename><surname>Uono</surname></persName><affiliation>National Shizuoka Hospital</affiliation></author><author><persName><forename type="first">Takao</forename><surname>Nakanishi</surname></persName><affiliation>Department of Neurology, University of Tsukuba</affiliation></author><author><persName><forename type="first">Masakuni</forename><surname>Kameyama</surname></persName><affiliation>Department of Neurology, University of Kyoto</affiliation></author><author><persName><forename type="first">Hitoshi</forename><surname>Ito</surname></persName><affiliation>Department of Psychiatry, Keio University</affiliation></author><author><persName><forename type="first">Yasuo</forename><surname>Shimada</surname></persName><affiliation>Shimada Hospital</affiliation></author><author><persName><forename type="first">Makoto</forename><surname>Iwata</surname></persName><affiliation>Department of Neurology, University of Tokyo</affiliation></author></analytic><monogr><title level="j">Acta Neurologica Scandinavica</title><idno type="pISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><idno type="DOI">10.1111/(ISSN)1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1985-08"></date><biblScope unit="volume">72</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="170">170</biblScope></imprint></monogr><idno type="istex">D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F</idno><idno type="DOI">10.1111/j.1600-0404.1985.tb00858.x</idno><idno type="ArticleID">ANE157</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1985</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>ABSTRACT – The effects of bromocriptine in patients with Parkinson's disease manifesting various problems in levodopa therapy were tested in a double‐blind manner with the collaboration of 59 institutions. The slow and low principle was in part adopted. Either bromocriptine or placebo was added to levodopa. Twenty‐nine % of the bromocriptine‐treated patients (n = 108), in contrast to 14.8% of the placebo‐treated (n = 108), showed either marked or moderate improvement (P < 0.05). Twenty to 37% improvement was noted in most of the symptoms studied in those treated with bromocriptine. The significant superiority of bromocriptine was also noted in the effects on wearing‐off phenomena and frozen gait. No irreversible side effects were noted. It is concluded that bromocriptine is useful in patients who are manifesting various difficulties in levodopa therapy. Our results are comparable to those using higher maintenance doses. Dopamine antagonistic actions were not observed. This is unlike the case with experimental animals.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Bromocriptine</term></item><item><term>double‐blind study</term></item><item><term>levodopa</term></item><item><term>Parkinsonism</term></item><item><term>Parkinson's disease</term></item><item><term>Japan</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1985-08">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0404</doi><issn type="print">0001-6314</issn><issn type="electronic">1600-0404</issn><idGroup><id type="product" value="ANE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA NEUROLOGICA SCANDINAVICA">Acta Neurologica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="08002"><doi origin="wiley">10.1111/ane.1985.72.issue-2</doi><numberingGroup><numbering type="journalVolume" number="72">72</numbering><numbering type="journalIssue" number="2">2</numbering></numberingGroup><coverDate startDate="1985-08">August 1985</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0015700" status="forIssue"><doi origin="wiley">10.1111/j.1600-0404.1985.tb00858.x</doi><idGroup><id type="unit" value="ANE157"></id></idGroup><countGroup><count type="pageTotal" number="14"></count></countGroup><titleGroup><title type="tocHeading1">Original articles</title></titleGroup><eventGroup><event type="firstOnline" date="2009-01-29"></event><event type="publishedOnlineFinalForm" date="2009-01-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:HeaderRef result:HeaderRef" date="2010-04-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="157">157</numbering><numbering type="pageLast" number="170">170</numbering></numberingGroup><correspondenceTo><i>Yoshikuni Mizuno</i>, M.D. Department of Neurology Jichi Medical School 3311 Yakushiji, Minamikawachi Tochigi Japan</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANE.ANE157.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Accepted for publication 4 March 1985</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="43"></count><count type="linksCrossRef" number="13"></count></countGroup><titleGroup><title type="main">Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Yasuo</givenNames><familyName>Toyokura</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2" corresponding="yes"><personName><givenNames>Yoshikuni</givenNames><familyName>Mizuno</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3"><personName><givenNames>Masao</givenNames><familyName>Kase</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a4"><personName><givenNames>Itsuro</givenNames><familyName>Sobue</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a5"><personName><givenNames>Yoshigoro</givenNames><familyName>Kuroiwa</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a6"><personName><givenNames>Hirotaro</givenNames><familyName>Narabayashi</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a7"><personName><givenNames>Masanori</givenNames><familyName>Uono</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a8"><personName><givenNames>Takao</givenNames><familyName>Nakanishi</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a9"><personName><givenNames>Masakuni</givenNames><familyName>Kameyama</familyName></personName></creator><creator creatorRole="author" xml:id="cr10" affiliationRef="#a10"><personName><givenNames>Hitoshi</givenNames><familyName>Ito</familyName></personName></creator><creator creatorRole="author" xml:id="cr11" affiliationRef="#a11"><personName><givenNames>Yasuo</givenNames><familyName>Shimada</familyName></personName></creator><creator creatorRole="author" xml:id="cr12" affiliationRef="#a1"><personName><givenNames>Makoto</givenNames><familyName>Iwata</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>Department of Neurology, University of Tokyo</unparsedAffiliation></affiliation><affiliation xml:id="a2"><unparsedAffiliation>Department of Neurology, Jichi Medical School</unparsedAffiliation></affiliation><affiliation xml:id="a3"><unparsedAffiliation>Segawa Neurology Clinic of Children</unparsedAffiliation></affiliation><affiliation xml:id="a4"><unparsedAffiliation>First Department of Medicine, University of Nagoya</unparsedAffiliation></affiliation><affiliation xml:id="a5"><unparsedAffiliation>Department of Neurology, Kyushu University</unparsedAffiliation></affiliation><affiliation xml:id="a6"><unparsedAffiliation>Department of Neurology, Juntendo University</unparsedAffiliation></affiliation><affiliation xml:id="a7"><unparsedAffiliation>National Shizuoka Hospital</unparsedAffiliation></affiliation><affiliation xml:id="a8"><unparsedAffiliation>Department of Neurology, University of Tsukuba</unparsedAffiliation></affiliation><affiliation xml:id="a9"><unparsedAffiliation>Department of Neurology, University of Kyoto</unparsedAffiliation></affiliation><affiliation xml:id="a10"><unparsedAffiliation>Department of Psychiatry, Keio University</unparsedAffiliation></affiliation><affiliation xml:id="a11"><unparsedAffiliation>Shimada Hospital</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Bromocriptine</keyword><keyword xml:id="k2">double‐blind study</keyword><keyword xml:id="k3">levodopa</keyword><keyword xml:id="k4">Parkinsonism</keyword><keyword xml:id="k5">Parkinson's disease</keyword><keyword xml:id="k6">Japan</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>ABSTRACT – </b> The effects of bromocriptine in patients with Parkinson's disease manifesting various problems in levodopa therapy were tested in a double‐blind manner with the collaboration of 59 institutions. The slow and low principle was in part adopted. Either bromocriptine or placebo was added to levodopa.</p><p>Twenty‐nine % of the bromocriptine‐treated patients (n = 108), in contrast to 14.8% of the placebo‐treated (n = 108), showed either marked or moderate improvement (<i>P</i> < 0.05). Twenty to 37% improvement was noted in most of the symptoms studied in those treated with bromocriptine. The significant superiority of bromocriptine was also noted in the effects on wearing‐off phenomena and frozen gait. No irreversible side effects were noted.</p><p>It is concluded that bromocriptine is useful in patients who are manifesting various difficulties in levodopa therapy. Our results are comparable to those using higher maintenance doses. Dopamine antagonistic actions were not observed. This is unlike the case with experimental animals.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study</title></titleInfo><name type="personal"><namePart type="given">Yasuo</namePart><namePart type="family">Toyokura</namePart><affiliation>Department of Neurology, University of Tokyo</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yoshikuni</namePart><namePart type="family">Mizuno</namePart><affiliation>Department of Neurology, Jichi Medical School</affiliation><description>Correspondence: , M.D. Department of Neurology Jichi Medical School 3311 Yakushiji, Minamikawachi Tochigi Japan</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Masao</namePart><namePart type="family">Kase</namePart><affiliation>Segawa Neurology Clinic of Children</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Itsuro</namePart><namePart type="family">Sobue</namePart><affiliation>First Department of Medicine, University of Nagoya</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yoshigoro</namePart><namePart type="family">Kuroiwa</namePart><affiliation>Department of Neurology, Kyushu University</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hirotaro</namePart><namePart type="family">Narabayashi</namePart><affiliation>Department of Neurology, Juntendo University</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Masanori</namePart><namePart type="family">Uono</namePart><affiliation>National Shizuoka Hospital</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Takao</namePart><namePart type="family">Nakanishi</namePart><affiliation>Department of Neurology, University of Tsukuba</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Masakuni</namePart><namePart type="family">Kameyama</namePart><affiliation>Department of Neurology, University of Kyoto</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hitoshi</namePart><namePart type="family">Ito</namePart><affiliation>Department of Psychiatry, Keio University</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yasuo</namePart><namePart type="family">Shimada</namePart><affiliation>Shimada Hospital</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Makoto</namePart><namePart type="family">Iwata</namePart><affiliation>Department of Neurology, University of Tokyo</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1985-08</dateIssued><edition>Accepted for publication 4 March 1985</edition><copyrightDate encoding="w3cdtf">1985</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">43</extent></physicalDescription><abstract lang="en">ABSTRACT – The effects of bromocriptine in patients with Parkinson's disease manifesting various problems in levodopa therapy were tested in a double‐blind manner with the collaboration of 59 institutions. The slow and low principle was in part adopted. Either bromocriptine or placebo was added to levodopa. Twenty‐nine % of the bromocriptine‐treated patients (n = 108), in contrast to 14.8% of the placebo‐treated (n = 108), showed either marked or moderate improvement (P < 0.05). Twenty to 37% improvement was noted in most of the symptoms studied in those treated with bromocriptine. The significant superiority of bromocriptine was also noted in the effects on wearing‐off phenomena and frozen gait. No irreversible side effects were noted. It is concluded that bromocriptine is useful in patients who are manifesting various difficulties in levodopa therapy. Our results are comparable to those using higher maintenance doses. Dopamine antagonistic actions were not observed. This is unlike the case with experimental animals.</abstract><subject lang="en"><genre>Keywords</genre><topic>Bromocriptine</topic><topic>double‐blind study</topic><topic>levodopa</topic><topic>Parkinsonism</topic><topic>Parkinson's disease</topic><topic>Japan</topic></subject><relatedItem type="host"><titleInfo><title>Acta Neurologica Scandinavica</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0001-6314</identifier><identifier type="eISSN">1600-0404</identifier><identifier type="DOI">10.1111/(ISSN)1600-0404</identifier><identifier type="PublisherID">ANE</identifier><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>157</start><end>170</end><total>14</total></extent></part></relatedItem><identifier type="istex">D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F</identifier><identifier type="DOI">10.1111/j.1600-0404.1985.tb00858.x</identifier><identifier type="ArticleID">ANE157</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001E65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:D9CCAF44E90C2E5D3BE1C482AC1684214A0F950F
|texte= Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study
}}
| This area was generated with Dilib version V0.6.23. |  |